of the very same guidelines, it is stated that “Somatic tumor testing for BRCA1 and BRCA2 pathogenic or likely pathogenic variants should be performed in women who do not carry a germline pathogenic or likely pathogenic BRCA1/2 variant” [9]. The gene discussed is BRCA1; the disease is neoplasm.